Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ganga Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was ₹1.53 Mil. Ganga Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹82.99 Mil. Therefore, Ganga Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 1.85%.
The historical rank and industry rank for Ganga Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
BOM:539680'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.38 Med: 1.21 Max: 3.7
Current: 1.28
During the past 12 years, Ganga Pharmaceuticals's highest Return-on-Tangible-Equity was 3.70%. The lowest was 0.38%. And the median was 1.21%.
BOM:539680's Return-on-Tangible-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.925
vs BOM:539680: 1.28
Ganga Pharmaceuticals (BOM:539680) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ganga Pharmaceuticals Return-on-Tangible-Equity Related Terms
Ganga Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Ganga Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ganga Pharmaceuticals Return-on-Tangible-Equity Chart
BOM:539680 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ganga Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ganga Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ganga Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ganga Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.85% mean?
Ganga Pharmaceuticals (BOM:539680) has a Return-on-Tangible-Equity of 1.85% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ganga Pharmaceuticals and its competitors. This is 53% above median its historical median of 1.21. Over the past decade, Ganga Pharmaceuticals' Return-on-Tangible-Equity has ranged from 0.38 to 3.70.
Is Ganga Pharmaceuticals' Return-on-Tangible-Equity too high?
Ganga Pharmaceuticals' current Return-on-Tangible-Equity of 1.85% is 53% above median its 10-year median of 1.21. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 3.70. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.93. Ganga Pharmaceuticals' value of 1.85% is 76.7% below this industry median. Overall, Ganga Pharmaceuticals has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ganga Pharmaceuticals' Return-on-Tangible-Equity compare to ZTS?
Ganga Pharmaceuticals' Return-on-Tangible-Equity of 1.85% can be compared against companies in the Drug Manufacturers industry. The industry median Return-on-Tangible-Equity is 7.93. Ganga Pharmaceuticals' value of 1.85% is 76.7% below this benchmark. Historically, Ganga Pharmaceuticals' own Return-on-Tangible-Equity has ranged from 0.38 to 3.70 over the past decade. While the company's 10-year median is 1.21 vs. the industry median of 7.93, Ganga Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.93, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ganga Pharmaceuticals's current Return-on-Tangible-Equity of 1.85% is 76.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ganga Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ganga Pharmaceuticals's current Return-on-Tangible-Equity is 1.85%, which is 53% above median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ganga Pharmaceuticals stock overvalued right now?
Ganga Pharmaceuticals (BOM:539680) has a current Return-on-Tangible-Equity of 1.85%. The stock's GF Value™ is ₹11.85, compared to a current price of ₹12.00 — trading 1.3% above its estimated fair value. The current Return-on-Tangible-Equity is 1.85%, which is 53% above median its 10-year median of 1.21 and 76.7% below the Drug Manufacturers industry median of 7.93. Ganga Pharmaceuticals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ganga Pharmaceuticals (BOM:539680), the current Return-on-Tangible-Equity is 1.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ganga Pharmaceuticals (BOM:539680) Overvalued in 2026?
Based on GuruFocus' analysis, Ganga Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹12.00 is trading 1.3% above its estimated GF Value™ of ₹11.85.
Key valuation signals for BOM:539680:
Return-on-Tangible-Equity: 1.85% (53% above median its 10-year median of 1.21)
GF Value™: ₹11.85 vs. price of ₹12.00 (1.3% above fair value)
Industry Position: 76.7% below the Drug Manufacturers median
No single metric tells the full story. See the BOM:539680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ganga Pharmaceuticals Ltd is an India based producer of ayurvedic medicines. It is engaged in the business of manufacturing and trading in ayurvedic pharmaceuticals and allied products. The company is also involved in the marketing and distribution of bulk ayurvedic medicines. The firm offers ayurvedic medicines for acidity, anti-dandruff, anti-oxidants, dental care, diarrhea, iron tonic, liver disorder, weight management, kidney stone, joint pains, liver disorder and others.
62GF Score
Get the complete analysis for BOM:539680
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539680 has been successfully added to your 
